Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hepatology›Condition·Updated Jun 27, 2026·v1

Primary Biliary Cholangitis

Primary Biliary Cholangitis is a chronic autoimmune cholestatic liver disease defined by AMA positivity and progressive bile duct destruction. First-line UDCA achieves biochemical response in ~60% of patients, normalizing transplant-free survival. Non-responders require second-line PPAR agonists (seladelpar, elafibranor, bezafibrate) or OCA to reduce progression risk. Pruritus and fatigue are common symptoms; decompensation events (ascites, variceal hemorrhage, encephalopathy) mark a poor prognosis but may be reversible with aggressive medical therapy. Liver transplantation is definitive for decompensated disease, with excellent survival but a 25-35% recurrence risk mitigated by post-transplant UDCA and cyclosporine.

High Evidence219 references·14,738 words·59 min read·v1
Primary Biliary CholangitisPBCcholestatic liver diseaseautoimmune liver diseaseAMAursodeoxycholic acidseladelparelafibranorobeticholic acidbezafibrateliver transplantationpruritus

Quick Reference

RxDrug of choiceUrsodeoxycholic acid (UDCA) 13-15 mg/kg/day orally in divided doses, first-line for all patients; continue indefinitely.
AltAlternativesObeticholic acid 5-10 mg daily (FXR agonist), seladelpar 10 mg daily (PPARδ agonist), elafibranor 80 mg daily (PPARα/δ agonist), bezafibrate 400 mg daily (off-label pan-PPAR agonist).
⊘AvoidObeticholic acid in Child-Pugh B/C cirrhosis (risk of decompensation); non-dihydropyridine CCBs (diltiazem, verapamil); corticosteroids for PBC itself.
DxTest of choiceAnti-mitochondrial antibody (AMA) by indirect immunofluorescence or AMA-M2 by ELISA, first-line serologic test; if negative, PBC-specific ANA (anti-gp210, anti-sp100).
ScKey scoreGLOBE score (≥0.30 at 12 months identifies high-risk patients) or UK-PBC risk score (>10% 10-year risk); Paris-II criteria (ALP ≤1.5× ULN, AST ≤1.5× ULN, normal bilirubin) define adequate biochemical response.
→When to referLiver transplantation evaluation for Child-Pugh ≥7, MELD-Na ≥15, refractory ascites, variceal hemorrhage, hepatic encephalopathy, HCC within Milan criteria, or intractable pruritus.
Start UDCA at diagnosis; assess response at 12 months; escalate to second-line PPAR agonist (preferred if pruritus) or OCA in non-responders; aim for ALP normalization and normal bilirubin to normalize life expectancy.
Primary Biliary Cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and cirrhosis. First-line therapy with ursodeoxycholic acid (UDCA) 13-15 mg/kg/day achieves biochemical response in ~60% of patients, normalizing transplant-free survival. Non-responders require second-line agents (obeticholic acid, seladelpar, elafibranor, or bezafibrate) to reduce progression risk. Pruritus and fatigue dominate symptoms; decompensation events (ascites, variceal hemorrhage, encephalopathy) mark a poor prognosis but may be reversible with aggressive medical therapy. Liver transplantation is definitive for decompensated disease, with excellent survival but a 25-35% recurrence risk mitigated by post-transplant UDCA and cyclosporine-based immunosuppression.

Overview and Recommendations

Background

  • •PBC, primary biliary cholangitis, is a chronic, autoimmune, cholestatic liver disease driven by non-suppurative destruction of small-to-medium-sized intrahepatic bile ducts, with prevalence rising to 24.6 per 100,000 globally and a 3:1 to 4:1 female predominance. The historic term 'primary biliary cirrhosis' has been abandoned because most patients never develop cirrhosis at diagnosis, and the current consensus designates the PBC-AIH presentation as a 'variant' rather than an overlap syndrome.
  • •The hallmark autoantibody, anti-mitochondrial antibody (AMA, M2 subtype), is present in ~95% of patients and targets the pyruvate dehydrogenase complex E2 subunit (PDC-E2) on cholangiocytes. PBC-specific antinuclear antibodies (anti-gp210, anti-sp100) confirm diagnosis in AMA-negative cases with >99% specificity.
  • •The paradigm shift in management, from UDCA monotherapy to a treat-to-target strategy of ALP normalization, was driven by the GLOBE and UK-PBC risk scores, which at 12 months of therapy identify the ~30-40% of patients with inadequate biochemical response who face a 10-year transplant-free survival of only 55-70% compared to 95% for responders.
  • •Pathogenesis follows a sequential cascade: autoimmune cholangiocyte destruction → cholestasis → toxic bile-acid accumulation → hepatocyte IRF3-dependent cell death → stellate-cell activation driven by and TGF-β2 → biliary fibrosis. Systemic symptoms (pruritus, fatigue) arise from distinct mechanisms: pruritus via autotaxin-generated lysophosphatidic acid (LPA) and IL-31; fatigue via cerebral abnormalities in the thalamus and basal ganglia.
  • •Genetic susceptibility is conferred by HLA-DR8 (DRB1*08) and >45 non-HLA loci (IL12A, IL12RB2, STAT4, IRF5, TYK2), all reinforcing IL-12/Th1 and IFN-γ pathways. Environmental triggers include recurrent E. coli UTIs (OR 2.7), smoking (OR 2.1), and xenobiotic exposure (nail polish, hair dyes).
  • •Untreated, PBC progresses to cirrhosis and decompensation; with adequate UDCA response, transplant-free survival matches the general population. The NNT with UDCA to prevent one liver transplant or death at 10 years is 26.

Evaluation

  • •Suspect PBC in any patient, especially a woman aged 40-60, with an unexplained elevation of alkaline phosphatase (ALP) in a cholestatic pattern, with or without symptoms of pruritus, fatigue, or sicca complex (dry eyes, dry mouth).
  • •Ask about pruritus (palms, soles, worse at night), fatigue (unrelieved by rest), sicca symptoms, right upper quadrant discomfort, and a history of recurrent urinary tract infections, smoking, or family history of autoimmune disease.
  • •Examine for hepatomegaly (10-30%), splenomegaly (portal hypertension), xanthelasmas/xanthomas (cholesterol deposits), hyperpigmentation of sun-exposed skin, and excoriations from chronic scratching. Stigmata of cirrhosis (spider angiomata, palmar erythema, caput medusae) appear late.
  • •Order liver biochemistry: ALP elevated 2-10 times ULN, GGT elevated in parallel, total bilirubin normal in early disease, aminotransferases (AST, ALT) usually <3× ULN. Bilirubin >2 mg/dL signals advanced histology and poor prognosis.
  • •Order serologic testing: AMA by indirect immunofluorescence (titer ≥1:40) or AMA-M2 by ELISA. If AMA-negative, test for PBC-specific ANA (anti-gp210, anti-sp100). Dual positivity for AMA and anti-gp210/sp100 has a positive predictive value >98% for biopsy-proven PBC.
  • •Additional autoantibodies with prognostic value include anti-hexokinase 1 (HK1) and anti-kelch-like 12 (KLHL12), which independently predict liver-related death or transplantation (HR 2.1 for anti-HK1).
  • •Assess fibrosis stage at diagnosis with vibration-controlled transient elastography (VCTE). LSM <7.0 kPa rules out advanced fibrosis (NPV >90%); LSM >12.0 kPa rules it in (PPV >85%). Values 7.0-12.0 kPa are indeterminate and may warrant liver biopsy.
  • •If VCTE is unavailable, calculate serum fibrosis scores: FIB-4 >3.25 has 85% specificity for advanced fibrosis; APRI >1.5 has 70% sensitivity.
  • •Liver biopsy is the gold standard for diagnosis when serology is inconclusive (AMA-negative, PBC-specific ANA absent) or when overlap with autoimmune hepatitis is suspected (ALT/AST >5× ULN). Histologic hallmarks: florid bile duct lesions with non-caseating epithelioid granulomas, lymphocytic infiltration, and progressive ductopenia. Ludwig staging: I (portal inflammation), II (periportal fibrosis), III (septal fibrosis), IV (cirrhosis).
  • •Perform abdominal ultrasound at diagnosis to exclude biliary obstruction, gallstones, and hepatic masses. Magnetic resonance cholangiopancreatography (MRCP) is reserved for atypical features (dominant strictures, suspicion of primary sclerosing cholangitis).
  • •Diagnostic algorithm: (1) Cholestatic LFTs → (2) AMA positive → diagnosis confirmed. If AMA-negative, test PBC-specific ANA. If both negative, perform liver biopsy.
  • •At diagnosis, evaluate for associated autoimmune conditions: TSH and anti-thyroid antibodies (autoimmune thyroid disease in 10-15%), IgA-tTG (celiac disease in 3.5%), and symptom-directed screening for Sjögren's syndrome (keratoconjunctivitis sicca, xerostomia).
  • •Consider PBC in patients with unexplained pruritus without biochemical abnormalities (can precede labs by years), in women with cholestasis of pregnancy that persists postpartum, and in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and unexplained ALP elevation (steatosis in 30-40% of PBC biopsies).
  • •Differential diagnosis includes: primary sclerosing cholangitis (young men, IBD, MRCP strictures, AMA-negative), autoimmune hepatitis (marked ALT/AST elevation, elevated IgG, interface hepatitis), drug-induced cholestasis (temporal association, resolves after withdrawal), sarcoidosis (non-caseating granulomas in multiple organs, AMA-negative), and MASLD (steatosis, metabolic risk factors, AMA-negative).

Management

  • •First-line therapy: Initiate ursodeoxycholic acid (UDCA) at 13-15 mg/kg/day orally in divided doses (usually 500-1000 mg daily) immediately upon diagnosis, to be continued indefinitely. UDCA reduces the hazard of liver transplantation or death by 54% (HR 0.46, 95% CI 0.40-0.52); NNT at 5 years = 10.
  • •Assess biochemical response after 12 months of UDCA using validated criteria. The preferred target is Paris-II criteria: ALP ≤1.5× ULN, AST ≤1.5× ULN, and total bilirubin ≤ ULN. A more stringent target, ALP normalization (≤ ULN) and bilirubin <0.6× ULN, is associated with the best transplant-free survival.
  • •If biochemical response is inadequate (ALP >1.5× ULN or bilirubin > ULN at 12 months), add second-line therapy. Three main classes are available: farnesoid X receptor (FXR) agonists, selective PPARδ agonists, and pan-PPAR or dual PPARα/δ agonists.
  • •Second-line therapy, Obeticholic acid (OCA): Start at 5 mg orally once daily; after 3 months, if tolerated and bilirubin remains stable, titrate to 10 mg once daily. Biochemical response rate (POISE criteria) 47% vs 10% placebo at 12 months. Pooled HR for death/LTx/events 0.63 (95% CI 0.41-0.97) in COBALT trial. Contraindicated in Child-Pugh B/C cirrhosis due to risk of decompensation. Monitor pruritus (occurs in 20-60%, dose-dependent) and LDL cholesterol.
  • •Second-line therapy, Seladelpar (selective PPARδ agonist): Dose 10 mg orally once daily. Composite biochemical response at 12 months 61.7% vs 20.0% placebo; ALP normalization 25.2% vs 0%. Reduces pruritus NRS by a mean of -3.0 points in patients with baseline itch ≥4/10. NNT for biochemical response = 4. Preferred in patients with moderate-to-severe pruritus.
  • •Second-line therapy, Elafibranor (dual PPARα/δ agonist): Dose 80 mg orally once daily. Composite biochemical response at 12 months 51% vs 4% placebo; ALP normalization 15% vs 0%. Improved transplant-free survival by GLOBE score. Also improves pruritus. Long-term safety data are still accumulating.
  • •Second-line alternative, Bezafibrate (pan-PPAR agonist): Off-label in many regions; dose 400 mg orally once daily. Composite response at 24 months 31% vs 0% placebo. Reduces pruritus VAS by -2.6 points (FITCH trial). Associated with improved transplant-free survival (HR 0.46, 95% CI 0.22-0.97) in Japanese cohort. Monitor renal function and creatine kinase.
  • •For patients with inadequate response to one second-line agent after 12 months, consider switching to an alternative second-line agent.
  • •Management of pruritus: First-line, cholestyramine 4-16 g/day (separate from UDCA and other medications by ≥4 hours). Second-line, rifampicin 150-300 mg twice daily (monitor LFTs every 2-4 weeks for hepatotoxicity). Third-line, naltrexone 25-50 mg once daily. PPAR agonists (seladelpar, elafibranor, bezafibrate) consistently reduce pruritus and are preferred when second-line PBC therapy is also indicated.
  • •Management of fatigue: Hypnosis (4 weekly sessions) improved PBC-40 fatigue score in an RCT; psychoeducation also beneficial. Screen for depression, sleep apnea, and hypothyroidism. No pharmacologic therapy (including modafinil) has proven effective in RCTs. Avoid protein restriction; ensure adequate caloric intake.
  • •Management of sicca syndrome: Artificial tears, saliva substitutes. Refer to rheumatology for coexisting Sjögren's syndrome if severe.
  • •Osteoporosis prevention: Measure bone mineral density (DXA) at diagnosis and every 2-3 years. Supplement calcium 1000-1200 mg/day and vitamin D 800-1000 IU/day. If T-score ≤ -2.5, start bisphosphonate (e.g., alendronate 70 mg weekly) or denosumab 60 mg subcutaneously every 6 months.
  • •Cirrhosis surveillance: Perform abdominal ultrasound with or without alpha-fetoprotein every 6 months for hepatocellular carcinoma (HCC) surveillance. Screen for esophageal varices by EGD at cirrhosis diagnosis; repeat every 1-3 years depending on variceal status.
  • •Vaccinations: Administer hepatitis A vaccine (two doses), hepatitis B vaccine (three doses), pneumococcal vaccine (PCV20 or PCV15 + PPSV23), annual influenza, COVID-19 per guidelines, and Tdap (then Td every 10 years). Live vaccines are contraindicated if on immunosuppression.
  • •Decompensation management, Ascites: Sodium restriction (<2 g/day) plus diuretics: 100-400 mg daily ± 40-160 mg daily. Large-volume paracentesis with albumin 6-8 g/L removed for tense ascites. Refractory ascites: consider TIPS.
  • •Decompensation management, Variceal hemorrhage: Immediate vasoactive therapy: terlipressin 2 mg IV bolus then 1-2 mg IV every 4-6 hours (or somatostatin 250 µg IV bolus then 250-500 µg/h infusion). Antibiotic prophylaxis: 1 g IV daily for 5-7 days. Urgent upper endoscopy with band ligation within 12 hours. Secondary prophylaxis: EVL + nonselective beta-blocker (propranolol 40-80 mg BID or 6.25-12.5 mg daily, titrated to HR 55-60 bpm).
  • •Decompensation management, Hepatic encephalopathy: Lactulose 30-45 mL orally every 1-2 hours until 2-3 soft stools/day, then titrate to 15-45 mL BID-TID. For persistent or recurrent HE, add rifaximin 550 mg BID. For grade 3-4 HE, ICU admission, airway protection, lactulose via NG tube or enema. Do NOT restrict dietary protein (target 1.2-1.5 g/kg/day).
  • •Decompensation management, Spontaneous bacterial peritonitis (SBP): Empiric 2 g IV every 8 hours for 5 days; add albumin 1.5 g/kg on day 1 then 1 g/kg on day 3 if creatinine >1 mg/dL, BUN >30 mg/dL, or bilirubin >4 mg/dL. Secondary prophylaxis: norfloxacin 400 mg orally daily (or co-trimoxazole double-strength daily) in high-risk patients (asciitic protein <1.5 g/dL plus renal dysfunction or severe liver disease).
  • •Hepatorenal syndrome (HRS-AKI): Diagnosis after diuretic withdrawal and albumin expansion (1 g/kg/day for 2 days) without response. First-line: terlipressin 0.5-1 mg IV every 4-6 hours (titrate to 2 mg q4-6h if needed) plus albumin 20-40 g IV daily. Alternative: norepinephrine 0.5-3 mg/h IV continuous infusion.
  • •Hepatic recompensation: Achievable in up to 40% of patients with decompensated PBC who achieve Paris-II biochemical response (ALP ≤1.5× ULN, AST ≤1.5× ULN, normal bilirubin) after optimization of UDCA ± second-line therapy. Recompensation is associated with improved transplant-free survival (HR 0.37, 95% CI 0.16-0.85).
  • •Liver transplantation referral: Indications, Child-Pugh score ≥7, MELD-Na ≥15, refractory ascites, recurrent variceal hemorrhage, hepatic encephalopathy, HCC within Milan criteria, intractable pruritus. Post-transplant: continue UDCA 13-15 mg/kg/day to reduce recurrence (OR 0.39). Prefer cyclosporine over tacrolimus for immunosuppression to lower recurrence risk (HR 0.61).
  • •What NOT to do: Do NOT use non-dihydropyridine CCBs (diltiazem, verapamil), no role in PBC. Do NOT use corticosteroids for PBC, no benefit, increased infection risk. Do NOT use OCA in Child-Pugh C cirrhosis. Do NOT restrict dietary protein in hepatic encephalopathy. Do NOT give aminoglycosides in SBP. Do NOT use vasopressin alone for variceal hemorrhage. Do NOT delay liver transplant evaluation in decompensated patients.

Board Review — High Yield

  • •Anti-mitochondrial antibody (AMA), Present in ~95% of PBC patients; targets PDC-E2; specificity >95%.
  • •UDCA 13-15 mg/kg/day, First-line therapy; reduces hazard of LTx/death by 54% (HR 0.46); NNT = 10 at 5 years.
  • •GLOBE score >0.30, Identifies patients with reduced 10-year transplant-free survival at 12 months; dictates need for second-line therapy.
  • •Paris-II criteria, ALP ≤1.5× ULN, AST ≤1.5× ULN, normal bilirubin at 12 months defines adequate biochemical response; non-responders have 10-year survival ~55%.
  • •Pruritus mechanism, Autotaxin-generated lysophosphatidic acid (LPA) and IL-31; PPAR agonists (seladelpar, bezafibrate) reduce itch.
  • •Seladelpar 10 mg daily, PPARδ agonist; 61.7% biochemical response at 12 months; reduces pruritus NRS by -3.0; preferred in patients with itch.
  • •PBC-AIH variant, 2026 Delphi consensus renamed from 'overlap syndrome'; requires corticosteroid therapy in addition to UDCA.
  • •Post-transplant recurrence, 25-35% at 5-10 years; reduced by UDCA prophylaxis (OR 0.39) and cyclosporine-based immunosuppression.
  • •Hepatic recompensation, Achievable in up to 40% of decompensated PBC patients who achieve Paris-II response; associated with improved survival.
  • •MELD purgatory, PBC patients are disadvantaged by MELD-based allocation; bilirubin out of proportion to other organ dysfunction leads to longer waitlist times and higher dropout.

Deep Dive — Evidence Details

References

  1. [1]

    . “EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis.” Journal of hepatology (2026). PMID: 42191456 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Prognosis & Natural History
  2. [2]

    Palmer M, Regev A, Lindor K et al.. “Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.” Alimentary pharmacology & therapeutics (2019). PMID: 31762074 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute Management & Decompensation Events
  3. [3]

    Gerussi A, Sebode M, Nofit E et al.. “Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus.” Hepatology (Baltimore, Md.) (2026). PMID: 42132745 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events
  4. [4]

    Sayiner M, Golabi P, Stepanova M et al.. “Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use.” Hepatology (Baltimore, Md.) (2019). PMID: 30015376 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Decompensation & Transplant Management, Complications
  5. [5]

    Braadland PR, Bergquist A, Kummen M et al.. “Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.” Journal of hepatology (2023). PMID: 37328069 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Decompensation & Transplant Management
  6. [6]

    Hartl J, Ehlken H, Sebode M et al.. “Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.” Journal of hepatology (2017). PMID: 29180000 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification
  7. [7]

    Sorrentino MC, Villalta D, Carbone T et al.. “Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) guidelines on the use of autoantibody tests in the diagnosis of autoimmune liver diseases.” Autoimmunity reviews (2026). PMID: 42176826 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  8. [8]

    Bowlus CL, Bittencourt PL, Bobat B et al.. “Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.” The American journal of gastroenterology (2026). PMID: 42148535 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management
  9. [9]

    Kowdley KV, Bowlus CL, Levy C et al.. “Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.” The American journal of gastroenterology (2022). PMID: 36729104 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  10. [10]

    Kimura M, Ogawa E, Harada K et al.. “Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.” BMJ open gastroenterology (2022). PMID: 36442892 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
  11. [11]

    Montano-Loza AJ, Corpechot C. “Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32629125 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management
  12. [12]

    Werner E, van Hooff MCB, Weijsters GHX et al.. “Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40246040 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Prognosis & Natural History
  13. [13]

    Lu M, Li J, Haller IV et al.. “Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 29066370 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
  14. [14]

    Li J, Tian S, Ci B et al.. “Serum vitamins and homocysteine levels in autoimmune liver disease: A systematic review and meta-analysis.” Immunity, inflammation and disease (2024). PMID: 38652023 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  15. [15]

    Kremer AE, Mayo MJ, Hirschfield GM et al.. “Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2023). PMID: 38117036 ↗

    L4RCTCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  16. [16]

    Oduyebo I, Camilleri M, Nelson AD et al.. “Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.” The American journal of gastroenterology (2018). PMID: 29717197 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  17. [17]

    Hitomi Y, Ueno K, Aiba Y et al.. “A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2024). PMID: 38652555 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  18. [18]

    Cordell HJ, Fryett JJ, Ueno K et al.. “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.” Journal of hepatology (2021). PMID: 34033851 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Special Populations & Prevention
  19. [19]

    Levy C, Kendrick S, Bowlus CL et al.. “GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 36343847 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management
  20. [20]

    Goh XE, Goh MX, Chen VL et al.. “Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40848912 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  21. [21]

    Zhuang Y, Ortega-Ribera M, Thevkar Nagesh P et al.. “Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.” Hepatology (Baltimore, Md.) (2023). PMID: 37725754 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History
  22. [22]

    Jalan-Sakrikar N, Guicciardi ME, O'Hara SP et al.. “Central role for cholangiocyte pathobiology in cholestatic liver diseases.” Hepatology (Baltimore, Md.) (2024). PMID: 39250501 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  23. [23]

    Zhang J, Lyu Z, Li B et al.. “P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.” Hepatology (Baltimore, Md.) (2023). PMID: 36799463 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  24. [24]

    Liu R, Li X, Zhu W et al.. “Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.” Hepatology (Baltimore, Md.) (2019). PMID: 30985008 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  25. [25]

    Ronca V, Davies SP, Oo YH et al.. “The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.” Hepatology (Baltimore, Md.) (2025). PMID: 39774114 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  26. [26]

    Jansen PL, Ghallab A, Vartak N et al.. “The ascending pathophysiology of cholestatic liver disease.” Hepatology (Baltimore, Md.) (2017). PMID: 27981592 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  27. [27]

    Labiano I, Agirre-Lizaso A, Olaizola P et al.. “TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.” Journal of hepatology (2022). PMID: 35750136 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  28. [28]

    Huang B, Lyu Z, Qian Q et al.. “NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.” Journal of hepatology (2022). PMID: 35753523 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Prognosis & Natural History
  29. [29]

    Li J, Zhu X, Zhang M et al.. “Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.” Journal of hepatology (2021). PMID: 33746084 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  30. [30]

    Pu X, Liu Y, Lyu Z et al.. “B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.” Journal of hepatology (2025). PMID: 40683604 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation, Severity, Staging & Risk Stratification
  31. [31]

    Chen R, Huang B, Lian M et al.. “A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.” Journal of hepatology (2023). PMID: 37659731 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  32. [32]

    Wong YJ, Lam L, Soret PA et al.. “Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.” Journal of hepatology (2025). PMID: 41047080 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  33. [33]

    Reich M, Spomer L, Klindt C et al.. “Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.” Journal of hepatology (2021). PMID: 33872692 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  34. [34]

    Yokoda RT, Carey EJ. “Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.” The American journal of gastroenterology (2019). PMID: 31169523 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Decompensation & Transplant Management
  35. [35]

    John BV, Khakoo NS, Schwartz KB et al.. “Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.” The American journal of gastroenterology (2021). PMID: 33989225 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Complications
  36. [36]

    Reddy A, Martins A, Bowlus CL et al.. “Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.” The American journal of gastroenterology (2026). PMID: 41769906 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  37. [37]

    Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S et al.. “Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.” The American journal of gastroenterology (2019). PMID: 30315285 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  38. [38]

    Dropmann A, Dooley S, Dewidar B et al.. “TGF-β2 silencing to target biliary-derived liver diseases.” Gut (2020). PMID: 31992593 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  39. [39]

    Luo PY, Ma M, Liu MC et al.. “Autophagy of Kupffer cells modulates CD8+ T cell activation in primary biliary cholangitis.” Gut (2025). PMID: 41371935 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  40. [40]

    Wang R, Li B, Huang B et al.. “Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.” Gastroenterology (2024). PMID: 38810839 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  41. [41]

    Gordon SC, Villamil A, Jacobson IM et al.. “Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.” Hepatology communications (2026). PMID: 41974026 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Decompensation & Transplant Management
  42. [42]

    Tanaka A, Ma X, Takahashi A et al.. “Primary biliary cholangitis.” Lancet (London, England) (2024). PMID: 39216494 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  43. [43]

    Qianlang R, Yanxin Z, Dejia X et al.. “Gut microbiota alterations in primary biliary cholangitis: a systematic review and meta-analysis.” Frontiers in microbiology (2026). PMID: 42358256 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup
  44. [44]

    Zhang Z. “Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics.” Frontiers in immunology (2026). PMID: 42148062 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management
  45. [45]

    Zhang M, Wang C, Huang Y et al.. “The Genomics/Genetics of Primary Biliary Cholangitis: The Case for a Functional SNP rs10893900 in ETS1/FLI1 and Review of the Literature.” Clinical reviews in allergy & immunology (2025). PMID: 41144175 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  46. [46]

    Kowdley KV, Ieyoub J, Pan Y et al.. “Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2025). PMID: 41163430 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  47. [47]

    Leung KK, Deeb M, Hirschfield GM. “Review article: pathophysiology and management of primary biliary cholangitis.” Alimentary pharmacology & therapeutics (2020). PMID: 32813299 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Special Populations & Prevention
  48. [48]

    Grover VP, Southern L, Dyson JK et al.. “Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.” Alimentary pharmacology & therapeutics (2016). PMID: 27604637 ↗

    L4OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification
  49. [49]

    Liwinski T, Casar C, Ruehlemann MC et al.. “A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis.” Alimentary pharmacology & therapeutics (2020). PMID: 32383181 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  50. [50]

    Gómez E, Montero JL, Molina E et al.. “Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.” Alimentary pharmacology & therapeutics (2024). PMID: 38690746 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation, Decompensation & Transplant Management, Prognosis & Natural History
  51. [51]

    Cholankeril G, Gonzalez HC, Satapathy SK et al.. “Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29427734 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  52. [52]

    Calvaruso V, Celsa C, Cristoferi L et al.. “Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39674236 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Decompensation & Transplant Management
  53. [53]

    Yang P, Zhang F, Wang F et al.. “Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report.” Frontiers in medicine (2025). PMID: 41393157 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Presentation
  54. [54]

    Huang Z, Zhang M, Zhang X et al.. “Novel Mechanistic Insights into Primary Biliary Cholangitis: From Pathogenesis to Mesenchymal Stem Cell-Mediated Repair.” Biomedicines (2026). PMID: 42193429 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  55. [55]

    Kimura K, Kohara M. “Reframing Wnt/β-Catenin Signalling in Liver Fibrosis: Transcriptional State Regulation by CBP and p300.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42188461 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  56. [56]

    Trivedi PJ, Hirschfield GM, Eric Gershwin M. “Can we cure primary biliary cholangitis?” Current opinion in immunology (2026). PMID: 42134016 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  57. [57]

    Kwo PY, Cohen SM, Lim JK. “ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.” The American journal of gastroenterology (2016). PMID: 27995906 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations & Prevention
  58. [58]

    Vuppalanchi R, Caldwell SH, Pyrsopoulos N et al.. “Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.” Journal of hepatology (2021). PMID: 34487750 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  59. [59]

    Hirschfield GM, Bowlus CL, Mayo MJ et al.. “A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.” The New England journal of medicine (2024). PMID: 38381664 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  60. [60]

    Montano-Loza AJ, Bhanji RA, Wasilenko S et al.. “Systematic review: recurrent autoimmune liver diseases after liver transplantation.” Alimentary pharmacology & therapeutics (2016). PMID: 27957759 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  61. [61]

    Pedersen MR, Greenan G, Arora S et al.. “Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 33185320 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Special Populations & Prevention
  62. [62]

    Tan JJ, Chung AH, Loo JH et al.. “Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40398833 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  63. [63]

    Tansel A, Katz LH, El-Serag HB et al.. “Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28215616 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications
  64. [64]

    Corpechot C, Lemoinne S, Soret PA et al.. “Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?” Hepatology (Baltimore, Md.) (2023). PMID: 37399238 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  65. [65]

    Cançado GGL, Deeb M, Gulamhusein AF. “Liver transplantation for cholestatic liver diseases: Timing and disease recurrence.” Hepatology (Baltimore, Md.) (2025). PMID: 39960305 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  66. [66]

    Mol B, Werner E, Culver EL et al.. “Epidemiological and economical burden of cholestatic liver disease.” Hepatology (Baltimore, Md.) (2025). PMID: 40168457 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management
  67. [67]

    Ampuero J, Lucena A, Berenguer M et al.. “Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy.” Hepatology (Baltimore, Md.) (2024). PMID: 38447019 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management
  68. [68]

    Yang Y, Choi J, Chen Y et al.. “E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.” Hepatology (Baltimore, Md.) (2021). PMID: 34608663 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  69. [69]

    Shuai Z, Wang J, Badamagunta M et al.. “The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2017). PMID: 28100006 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  70. [70]

    Harms MH, van Buuren HR, Corpechot C et al.. “Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.” Journal of hepatology (2019). PMID: 30980847 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Prognosis & Natural History
  71. [71]

    Corpechot C, Carrat F, Gaouar F et al.. “Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.” Journal of hepatology (2022). PMID: 35777587 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  72. [72]

    Montano-Loza AJ, Lytvyak E, Hirschfield G et al.. “Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.” Journal of hepatology (2024). PMID: 38821360 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  73. [73]

    Tanaka A, Hirohara J, Nakano T et al.. “Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.” Journal of hepatology (2021). PMID: 33882268 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  74. [74]

    Corpechot C, Chazouillères O, Belnou P et al.. “Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.” Journal of hepatology (2020). PMID: 32275981 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications
  75. [75]

    Probert PM, Leitch AC, Dunn MP et al.. “Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.” Journal of hepatology (2018). PMID: 30006067 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  76. [76]

    Floreani A, Mangini C, Reig A et al.. “Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.” The American journal of gastroenterology (2016). PMID: 27779196 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Decompensation & Transplant Management, Prognosis & Natural History
  77. [77]

    Hercun J, Noureddin M, Noureddin N et al.. “Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis.” The American journal of gastroenterology (2022). PMID: 36066458 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  78. [78]

    Gordon SC, Wu KH, Lindor K et al.. “Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.” The American journal of gastroenterology (2020). PMID: 31985529 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
  79. [79]

    Harms MH, Lammers WJ, Thorburn D et al.. “Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.” The American journal of gastroenterology (2017). PMID: 29231188 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Complications
  80. [80]

    Trivedi PJ, Hirschfield GM. “Recent advances in clinical practice: epidemiology of autoimmune liver diseases.” Gut (2021). PMID: 34266966 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
  81. [81]

    Zingone F, Bai JC, Cellier C et al.. “Celiac Disease-Related Conditions: Who to Test?” Gastroenterology (2024). PMID: 38460606 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Special Populations & Prevention
  82. [82]

    Trivedi PJ, Hirschfield GM, Adams DH et al.. “Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts.” Gastroenterology (2024). PMID: 38342195 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management
  83. [83]

    Levy C, Bowlus CL, Lawitz E et al.. “Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41937506 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Complications, Prognosis & Natural History
  84. [84]

    Chung AH, Tan JJ, Yap RXJ et al.. “Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis.” Hepatology communications (2026). PMID: 42118984 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management
  85. [85]

    Tan JJ, Lytvyak E, Quek JWE et al.. “Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis.” Hepatology communications (2026). PMID: 42043878 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Complications
  86. [86]

    Nguyen B, Quon S, Powar A et al.. “Comparative waitlist mortality of autoimmune liver disease: A systematic review and meta-analysis.” Transplantation reviews (Orlando, Fla.) (2026). PMID: 42035504 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  87. [87]

    Passos PRC, Filho VOC, Noronha MM et al.. “Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 41135886 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Prognosis & Natural History
  88. [88]

    Liu HL, Liu X, Hu YF et al.. “Dual Positivity for AMA/AMA-M2 and Anti-gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2026). PMID: 41845567 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  89. [89]

    Kowdley KV, Victor DW, MacEwan JP et al.. “Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population-Based Study.” Alimentary pharmacology & therapeutics (2025). PMID: 40176393 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management
  90. [90]

    Hernández-Pérez M, Riado D, Pena E et al.. “The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis.” Alimentary pharmacology & therapeutics (2024). PMID: 38924185 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History
  91. [91]

    Harms MH, Janssen QP, Adam R et al.. “Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades.” Alimentary pharmacology & therapeutics (2018). PMID: 30561112 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management
  92. [92]

    Peverelle M, Campbell SMA, Peverelle J et al.. “Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.” Alimentary pharmacology & therapeutics (2026). PMID: 41953994 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications
  93. [93]

    Nilsson E, Anderson H, Sargenti K et al.. “Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.” Alimentary pharmacology & therapeutics (2019). PMID: 30957910 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Decompensation & Transplant Management, Complications
  94. [94]

    Jones O, Claasen MPAW, Ivanics T et al.. “Pursuing living donor liver transplantation improves outcomes of patients with autoimmune liver diseases: An intention-to-treat analysis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 38619393 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  95. [95]

    Gerussi A, Nofit E, Bernasconi DP et al.. “Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER).” United European gastroenterology journal (2025). PMID: 41124063 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events
  96. [96]

    Lam L, Soret PA, Lemoinne S et al.. “Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39019421 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  97. [97]

    Lu M, Zhou Y, Haller IV et al.. “Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 29277621 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Complications, Prognosis & Natural History
  98. [98]

    Lamba M, Ngu JH, Stedman CAM. “Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32526342 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  99. [99]

    Stockdale AJ, Kreuels B, Shawa IT et al.. “Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control study.” The Lancet. Global health (2025). PMID: 41109263 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications
  100. [100]

    . “EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.” Journal of hepatology (2017). PMID: 28427765 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Special Populations & Prevention
  101. [101]

    Hirschfield GM, Dyson JK, Alexander GJM et al.. “The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.” Gut (2018). PMID: 29593060 ↗

    L1GUIDELINECited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Prognosis & Natural History
  102. [102]

    Kowdley KV, Hirschfield GM, Coombs C et al.. “COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.” The American journal of gastroenterology (2024). PMID: 39140490 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Decompensation & Transplant Management
  103. [103]

    Brookhart MA, Mayne TJ, Coombs C et al.. “Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.” Hepatology (Baltimore, Md.) (2025). PMID: 39630028 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Long-term & Definitive Management, Prognosis & Natural History
  104. [104]

    Murillo Perez CF, Fisher H, Hiu S et al.. “Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.” Gastroenterology (2022). PMID: 36150526 ↗

    L2RCTCited in: Clinical Presentation, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  105. [105]

    Mayo MJ. “Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?” Hepatology (Baltimore, Md.) (2022). PMID: 35152430 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management, Prognosis & Natural History
  106. [106]

    Cristoferi L, Calvaruso V, Overi D et al.. “Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach.” Hepatology (Baltimore, Md.) (2021). PMID: 33724515 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup
  107. [107]

    Choi J, Xu J, Nguyen VH et al.. “Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.” Hepatology (Baltimore, Md.) (2026). PMID: 41627867 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup, Decompensation & Transplant Management, Complications
  108. [108]

    Roberts SB, Hirschfield GM, Worobetz LJ et al.. “Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2022). PMID: 35220609 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Prognosis & Natural History
  109. [109]

    John BV, Aitcheson G, Schwartz KB et al.. “Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.” Hepatology (Baltimore, Md.) (2021). PMID: 33636012 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Complications
  110. [110]

    van Hooff MC, de Veer RC, Werner E et al.. “Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study.” The American journal of gastroenterology (2025). PMID: 41363724 ↗

    L4OTHERCited in: Clinical Presentation, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  111. [111]

    Reig A, Norman GL, Garcia M et al.. “Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.” The American journal of gastroenterology (2020). PMID: 32467507 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification
  112. [112]

    Reig A, Sesé P, Parés A. “Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.” The American journal of gastroenterology (2017). PMID: 29016567 ↗

    L4OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Complications
  113. [113]

    Hofer BS, Burghart L, Halilbasic E et al.. “Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.” Alimentary pharmacology & therapeutics (2024). PMID: 38409879 ↗

    L3OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  114. [114]

    Abbas N, Smith R, Lytvyak E et al.. “Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2025). PMID: 40977287 ↗

    L3OTHERCited in: Clinical Presentation, Long-term & Definitive Management, Complications, Prognosis & Natural History
  115. [115]

    Cheung AC, Lapointe-Shaw L, Kowgier M et al.. “Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.” Alimentary pharmacology & therapeutics (2015). PMID: 26559762 ↗

    L3OTHERCited in: Clinical Presentation
  116. [116]

    Dyson JK, Wilkinson N, Jopson L et al.. “The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.” Alimentary pharmacology & therapeutics (2016). PMID: 27640331 ↗

    L4OTHERCited in: Clinical Presentation
  117. [117]

    Nakadai Y, Ojiro K, Kasuga R et al.. “Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.” Journal of gastroenterology (2025). PMID: 41076613 ↗

    L3COHORTCited in: Clinical Presentation, Acute Management & Decompensation Events, Decompensation & Transplant Management
  118. [118]

    Park Y, Lee JJ, Ju JH et al.. “Clinical Characterization of Autoimmune Hepatic Involvement in Sjogren's Disease: A Retrospective Cohort Study in Korea.” International journal of molecular sciences (2025). PMID: 40565197 ↗

    L4COHORTCited in: Clinical Presentation
  119. [119]

    Gatselis NK, Goet JC, Zachou K et al.. “Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31419573 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History
  120. [120]

    Yoon P, Shen A, Chen M et al.. “Alkaline Phosphatase Normalization Occurs Less Frequently in Hispanic Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41620193 ↗

    L3OTHERCited in: Clinical Presentation
  121. [121]

    Nursoy M, Mehmetoglu E, Syal A et al.. “Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes.” Journal of scleroderma and related disorders (2026). PMID: 42256626 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications
  122. [122]

    Schattenberg JM, Pares A, Kowdley KV et al.. “A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.” Journal of hepatology (2021). PMID: 33484775 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management
  123. [123]

    Kowdley KV, Vuppalanchi R, Levy C et al.. “A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.” Journal of hepatology (2020). PMID: 32165251 ↗

    L1RCTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
  124. [124]

    Bowlus CL, Pockros PJ, Kremer AE et al.. “Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31606455 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management
  125. [125]

    Trivedi PJ, Arndtz K, Abbas N et al.. “Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study.” Alimentary pharmacology & therapeutics (2024). PMID: 38571284 ↗

    L2COHORTCited in: Diagnosis & Workup, Prognosis & Natural History
  126. [126]

    Levy C, Bowlus CL. “Primary biliary cholangitis: Personalizing second-line therapies.” Hepatology (Baltimore, Md.) (2024). PMID: 39707635 ↗

    L4REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management
  127. [127]

    Younossi ZM, Bernstein D, Shiffman ML et al.. “Diagnosis and Management of Primary Biliary Cholangitis.” The American journal of gastroenterology (2019). PMID: 30429590 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management
  128. [128]

    Levy C, Bowlus CL. “Role of Antinuclear Antibodies in Primary Biliary Cholangitis.” The American journal of gastroenterology (2020). PMID: 32701734 ↗

    L4OTHERCited in: Diagnosis & Workup, Prognosis & Natural History
  129. [129]

    Montano-Loza AJ, Hansen BE, Corpechot C et al.. “Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.” Gastroenterology (2018). PMID: 30296431 ↗

    L2OTHERCited in: Diagnosis & Workup, Decompensation & Transplant Management, Prognosis & Natural History
  130. [130]

    Dunn S, Evans L, Kennedy C et al.. “Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.” BMJ open (2026). PMID: 41813047 ↗

    L1TRIAL_NONRANDOMCited in: Diagnosis & Workup, Acute Management & Decompensation Events, Prognosis & Natural History
  131. [131]

    Saeed M, Shaikh MS, Binhezaim A et al.. “Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review.” Frontiers in medicine (2026). PMID: 41625760 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  132. [132]

    Lin H, Zheng M, Huang Y et al.. “Lymphocyte-to-Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2025). PMID: 40546022 ↗

    L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  133. [133]

    Sorda JA, González Ballerga E, Barreyro FJ et al.. “Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.” Alimentary pharmacology & therapeutics (2021). PMID: 34587309 ↗

    L2OTHERCited in: Diagnosis & Workup
  134. [134]

    Gomez E, Garcia Buey L, Molina E et al.. “Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.” Alimentary pharmacology & therapeutics (2020). PMID: 33314220 ↗

    L2OTHERCited in: Diagnosis & Workup
  135. [135]

    Murillo Perez CF, Hirschfield GM, Corpechot C et al.. “Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.” Alimentary pharmacology & therapeutics (2019). PMID: 31621931 ↗

    L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
  136. [136]

    Montano-Loza AJ, Corpechot C, Burra P et al.. “Recurrence of autoimmune liver diseases after liver transplantation: Review and expert opinion statement.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 38857316 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  137. [137]

    Delle Cave V, Di Dato F, Calvo PL et al.. “Can liver biopsy be spared for the diagnosis of autoimmune hepatitis in selected children? A multicenter retrospective study.” Annals of hepatology (2026). PMID: 41796745 ↗

    L3COHORTCited in: Diagnosis & Workup, Special Populations & Prevention
  138. [138]

    Abbas N, Culver EL, Thorburn D et al.. “UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35961518 ↗

    L2OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  139. [139]

    Hegade VS, Mells GF, Fisher H et al.. “Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30557739 ↗

    L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events
  140. [140]

    Webb GJ, Ryan RP, Marshall TP et al.. “The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33493696 ↗

    L2OTHERCited in: Diagnosis & Workup
  141. [141]

    Huang M, Dai A, Gao L et al.. “Glasgow Prognostic Score Predicts Hepatic Recompensation in Decompensated Primary Biliary Cholangitis: A Multicenter Cohort Study.” Journal of inflammation research (2026). PMID: 42266451 ↗

    L3COHORTCited in: Diagnosis & Workup
  142. [142]

    Franke A, Müller T, Stein K et al.. “Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting.” Annals of hepatology (2026). PMID: 42285227 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup, Long-term & Definitive Management
  143. [143]

    Sheng LP, Zhang YY, Zhang M et al.. “Case Report: Systemic amyloidosis unmasked by progressive hepatomegaly after splenectomy for non-traumatic spleen rupture in a patient with chronic liver disease.” Frontiers in medicine (2026). PMID: 42100269 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup
  144. [144]

    Radice R, Pollaroli G, Salvatici M et al.. “The Role of Laboratory Markers in Primary Biliary Cholangitis: A Clinical Review and a Case Report.” Biomedicines (2026). PMID: 42072466 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup, Acute Management & Decompensation Events
  145. [145]

    Khanna A, Jopson L, Howel D et al.. “Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial.” Hepatology (Baltimore, Md.) (2018). PMID: 29790196 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  146. [146]

    Hegade VS, Kendrick SF, Dobbins RL et al.. “Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.” Lancet (London, England) (2017). PMID: 28187915 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
  147. [147]

    Levy C, Jones DEJ, Mayo MJ et al.. “Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.” Alimentary pharmacology & therapeutics (2026). PMID: 41933275 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  148. [148]

    Martins A, Khakoo NS, Corpechot C et al.. “Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2026). PMID: 41869905 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
  149. [149]

    Königshofer P, Hofer BS, Brusilovskaya K et al.. “Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.” Hepatology (Baltimore, Md.) (2021). PMID: 34716927 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management
  150. [150]

    Li Y, Li B, Xiao X et al.. “Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.” Hepatology (Baltimore, Md.) (2023). PMID: 37505225 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  151. [151]

    Younossi ZM, Kremer AE, Swain MG et al.. “Assessment of fatigue and its impact in chronic liver disease.” Journal of hepatology (2024). PMID: 38670320 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History
  152. [152]

    Guldiken N, Kobazi Ensari G, Lahiri P et al.. “Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease.” Journal of hepatology (2016). PMID: 27151178 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events
  153. [153]

    Murillo Perez CF, Harms MH, Lindor KD et al.. “Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.” The American journal of gastroenterology (2020). PMID: 32618657 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  154. [154]

    Goet JC, Murillo Perez CF, Harms MH et al.. “A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.” The American journal of gastroenterology (2021). PMID: 33941746 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management
  155. [155]

    Lang S, Demir M, Martin A et al.. “Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.” Gastroenterology (2020). PMID: 32652145 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  156. [156]

    Hirschfield GM, Bowlus CL, Jones DEJ et al.. “Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.” The lancet. Gastroenterology & hepatology (2025). PMID: 41173016 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  157. [157]

    Díaz-González Á, Molera C, Gómez-Domínguez E et al.. “Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP.” Gastroenterologia y hepatologia (2025). PMID: 41232665 ↗

    L1GUIDELINECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Decompensation & Transplant Management, Prognosis & Natural History, Special Populations & Prevention
  158. [158]

    de Veer RC, Harms MH, Corpechot C et al.. “Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.” Alimentary pharmacology & therapeutics (2022). PMID: 36138566 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Prognosis & Natural History
  159. [159]

    Gungabissoon U, Hunnicutt J, McDermott EJ et al.. “Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study.” BMJ open gastroenterology (2025). PMID: 41381205 ↗

    L2COHORTCited in: Severity, Staging & Risk Stratification
  160. [160]

    Mandea M, Iacob SM, Ghioca MC et al.. “Profile of Patients with Primary Biliary Cholangitis and Evaluation of Response to Ursodeoxycholic Acid in a Romanian Center-Retrospective Study.” Journal of clinical medicine (2025). PMID: 41303284 ↗

    L4COHORTCited in: Severity, Staging & Risk Stratification
  161. [161]

    Levy C, Manns M, Hirschfield G. “New Treatment Paradigms in Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 36809835 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Special Populations & Prevention
  162. [162]

    Hansen L, Chang MF, Hiatt S et al.. “Symptom Classes in Decompensated Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34813941 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management
  163. [163]

    Zheng L, Tian S, Yang C et al.. “Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38354969 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Prognosis & Natural History
  164. [164]

    Webb GJ, Rana A, Hodson J et al.. “Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28993258 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  165. [165]

    Jones DEJ, Beuers U, Bonder A et al.. “Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?” Hepatology (Baltimore, Md.) (2024). PMID: 38506926 ↗

    L5OTHERCited in: Acute Management & Decompensation Events, Long-term & Definitive Management, Prognosis & Natural History
  166. [166]

    Carbone M, Sharp SJ, Flack S et al.. “The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2015). PMID: 26223498 ↗

    L2OTHERCited in: Acute Management & Decompensation Events
  167. [167]

    Efe C, Taşçilar K, Henriksson I et al.. “Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.” The American journal of gastroenterology (2019). PMID: 31241547 ↗

    L2OTHERCited in: Acute Management & Decompensation Events
  168. [168]

    Werner E, van Hooff MCB, Weijsters GHX et al.. “A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.” Alimentary pharmacology & therapeutics (2026). PMID: 41979410 ↗

    L3OTHERCited in: Acute Management & Decompensation Events, Long-term & Definitive Management
  169. [169]

    Yang F, Yang Y, Wang Q et al.. “The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.” Alimentary pharmacology & therapeutics (2017). PMID: 28083929 ↗

    L3OTHERCited in: Acute Management & Decompensation Events
  170. [170]

    Yahia A, Baker FA, Tatour M et al.. “Reevaluating the clinical course of AMA-positive patients with normal liver enzymes: A large retrospective cohort study.” Annals of hepatology (2025). PMID: 41201643 ↗

    L3COHORTCited in: Acute Management & Decompensation Events, Decompensation & Transplant Management, Complications
  171. [171]

    Massironi S, Dispinzieri G, Rossi A et al.. “Immunological and clinical overlap between autoimmune gastritis and autoimmune liver diseases: a prospective cohort study.” Frontiers in immunology (2025). PMID: 40787461 ↗

    L2COHORTCited in: Acute Management & Decompensation Events, Special Populations & Prevention
  172. [172]

    Younossi ZM, Stepanova M, Ong J et al.. “Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32531342 ↗

    L2OTHERCited in: Acute Management & Decompensation Events, Decompensation & Transplant Management, Complications
  173. [173]

    Rice S, Albani V, Minos D et al.. “Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32562892 ↗

    L2OTHERCited in: Acute Management & Decompensation Events, Decompensation & Transplant Management
  174. [174]

    Hirschfield GM, Shiffman ML, Gulamhusein A et al.. “Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.” Hepatology (Baltimore, Md.) (2023). PMID: 37386786 ↗

    L1RCTCited in: Long-term & Definitive Management
  175. [175]

    Bowlus CL, Galambos MR, Aspinall RJ et al.. “A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.” Journal of hepatology (2022). PMID: 35367282 ↗

    L1RCTCited in: Long-term & Definitive Management
  176. [176]

    Liu Y, Guo G, Zheng L et al.. “Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.” The American journal of gastroenterology (2023). PMID: 36892506 ↗

    L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  177. [177]

    Untas A, Goffette C, Flahault C et al.. “PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue.” The American journal of gastroenterology (2025). PMID: 40658125 ↗

    L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  178. [178]

    de Vries E, Bolier R, Goet J et al.. “Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.” Gastroenterology (2020). PMID: 33031833 ↗

    L1RCTCited in: Long-term & Definitive Management
  179. [179]

    Kowdley KV, Bowlus CL, Levy C et al.. “Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.” The New England journal of medicine (2023). PMID: 37962077 ↗

    L1RCTCited in: Long-term & Definitive Management
  180. [180]

    Corpechot C, Chazouillères O, Rousseau A et al.. “A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.” The New England journal of medicine (2018). PMID: 29874528 ↗

    L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  181. [181]

    Nevens F, Andreone P, Mazzella G et al.. “A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.” The New England journal of medicine (2016). PMID: 27532829 ↗

    L1RCTCited in: Long-term & Definitive Management, Decompensation & Transplant Management
  182. [182]

    Maxwell M, Deng Y, Chen B et al.. “Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41705340 ↗

    L4COHORTCited in: Long-term & Definitive Management
  183. [183]

    Du Y, Khandekar G, Llewellyn J et al.. “A Bile Duct-on-a-Chip With Organ-Level Functions.” Hepatology (Baltimore, Md.) (2019). PMID: 31465556 ↗

    L5OTHERCited in: Long-term & Definitive Management
  184. [184]

    Beuers U, Banales JM, Karpen SJ et al.. “The history and future of bile acid therapies.” Journal of hepatology (2025). PMID: 40545045 ↗

    L5OTHERCited in: Long-term & Definitive Management, Special Populations & Prevention
  185. [185]

    Bhushan S, Sohal A, Kowdley KV. “Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.” The American journal of gastroenterology (2024). PMID: 39480026 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Decompensation & Transplant Management
  186. [186]

    Levy C, Trivedi PJ, Kowdley KV et al.. “Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.” The American journal of gastroenterology (2025). PMID: 40553148 ↗

    L4OTHERCited in: Long-term & Definitive Management
  187. [187]

    Reig A, Álvarez-Navascués C, Vergara M et al.. “Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.” The American journal of gastroenterology (2021). PMID: 34158466 ↗

    L2OTHERCited in: Long-term & Definitive Management
  188. [188]

    Tang R, Wei Y, Li Y et al.. “Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy.” Gut (2017). PMID: 28213609 ↗

    L3OTHERCited in: Long-term & Definitive Management
  189. [189]

    Harms MH, de Veer RC, Lammers WJ et al.. “Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.” Gut (2019). PMID: 31843787 ↗

    L2OTHERCited in: Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History
  190. [190]

    Lleo A, Wang GQ, Gershwin ME et al.. “Primary biliary cholangitis.” Lancet (London, England) (2020). PMID: 33308474 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  191. [191]

    Zhang J, Xiu T, Shen Q. “Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses.” Frontiers in pharmacology (2026). PMID: 42266365 ↗

    L1SR_OBSCited in: Long-term & Definitive Management, Prognosis & Natural History
  192. [192]

    Schattenberg JM, Banales JM, Hirschfield G et al.. “Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2026). PMID: 41906662 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Special Populations & Prevention
  193. [193]

    Kuo SZ, Yin J, Loomba R. “Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis.” Alimentary pharmacology & therapeutics (2025). PMID: 41163419 ↗

    L4OTHERCited in: Long-term & Definitive Management
  194. [194]

    De Vincentis A, Ampuero J, Terracciani F et al.. “Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38782175 ↗

    L2OTHERCited in: Long-term & Definitive Management
  195. [195]

    Jones D, Combe E, Knight H et al.. “Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.” Journal of comparative effectiveness research (2026). PMID: 41995445 ↗

    L1SR_OBSCited in: Long-term & Definitive Management
  196. [196]

    Zheng M, Lei H, He H et al.. “Prognostic nutritional index as a predictor of ursodeoxycholic acid response in primary biliary cholangitis: a retrospective study.” BMC gastroenterology (2026). PMID: 42343243 ↗

    L4COHORTCited in: Long-term & Definitive Management
  197. [197]

    Schneider KM, Kummen M, Trivedi PJ et al.. “Role of microbiome in autoimmune liver diseases.” Hepatology (Baltimore, Md.) (2023). PMID: 37369002 ↗

    L5REVIEW_NARRATIVECited in: Decompensation & Transplant Management
  198. [198]

    Honda A, Tanaka A, Kaneko T et al.. “Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.” Hepatology (Baltimore, Md.) (2019). PMID: 30737815 ↗

    L3OTHERCited in: Decompensation & Transplant Management
  199. [199]

    Gallo C, Invernizzi P. “Hepatic arterioportal fistula after biopsy conditioning portal hypertension: first case in primary biliary cholangitis and a systematic literature review.” Annals of hepatology (2025). PMID: 40383369 ↗

    L4SR_OBSCited in: Decompensation & Transplant Management
  200. [200]

    Heinemann M, Adam R, Berenguer M et al.. “Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2020). PMID: 32112516 ↗

    L2OTHERCited in: Decompensation & Transplant Management, Prognosis & Natural History
  201. [201]

    Wunsch E, Stadnik A, Kruk B et al.. “Chronic Fatigue Persists in a Significant Proportion of Female Patients After Transplantation for Primary Sclerosing Cholangitis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 33641247 ↗

    L2OTHERCited in: Decompensation & Transplant Management
  202. [202]

    Gerussi A, Bernasconi DP, O'Donnell SE et al.. “Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32777554 ↗

    L2OTHERCited in: Decompensation & Transplant Management
  203. [203]

    Zhong H, Zheng M, Zhao C et al.. “Primary biliary cholangitis with inflammation involving zone 3 of the liver has a poor response to ursodeoxycholic acid treatment: a retrospective cohort study.” BMC gastroenterology (2026). PMID: 41680693 ↗

    L2COHORTCited in: Decompensation & Transplant Management
  204. [204]

    Samur S, Klebanoff M, Banken R et al.. “Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2017). PMID: 27906472 ↗

    L2OTHERCited in: Complications
  205. [205]

    Dahlqvist G, Gaouar F, Carrat F et al.. “Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.” Hepatology (Baltimore, Md.) (2016). PMID: 27688145 ↗

    L2OTHERCited in: Complications
  206. [206]

    Schmidt T, Schwinge D, Rolvien T et al.. “Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.” Journal of hepatology (2019). PMID: 30641095 ↗

    L4OTHERCited in: Complications
  207. [207]

    Arase Y, Okubo T, Arai T et al.. “Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.” Hepatology communications (2025). PMID: 41056494 ↗

    L1RCTCited in: Complications
  208. [208]

    Mandea M, Oancea DM, Ghioca MC et al.. “The Significance of Enzymatic Cholestasis in Inflammatory Bowel Disease Patients for the Diagnosis of Primary Sclerosing Cholangitis-A Retrospective Study.” Journal of clinical medicine (2025). PMID: 40869741 ↗

    L2COHORTCited in: Complications
  209. [209]

    Jiang P, Feng Z, Sheng L et al.. “Morphological, Functional, and Tissue Characterization of Silent Myocardial Involvement in Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34461299 ↗

    L3OTHERCited in: Complications, Special Populations & Prevention
  210. [210]

    van den Brand FF, van der Veen KS, de Boer YS et al.. “Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30291909 ↗

    L2OTHERCited in: Complications, Prognosis & Natural History
  211. [211]

    Cheung AC, Lammers WJ, Murillo Perez CF et al.. “Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 30616022 ↗

    L2OTHERCited in: Complications
  212. [212]

    Martins A, Khakoo NS, Reddy A et al.. “Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.” Hepatology (Baltimore, Md.) (2025). PMID: 41052304 ↗

    L1SR_OBSCited in: Prognosis & Natural History
  213. [213]

    Li P, Wang Q, Yang Y et al.. “Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.” Frontiers in immunology (2025). PMID: 41425574 ↗

    L2SR_OBSCited in: Prognosis & Natural History, Special Populations & Prevention
  214. [214]

    de Vries E, Beuers U. “Ursodeoxycholic acid in pregnancy?” Journal of hepatology (2019). PMID: 31479696 ↗

    L4CASE_REPORTCited in: Special Populations & Prevention
  215. [215]

    Zingone F, Canova C, Forss A et al.. “Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.” Liver international : official journal of the International Association for the Study of the Liver (2025). PMID: 40827883 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  216. [216]

    Wang H, Gong J, Chen J et al.. “Intestinal microbiota and biliary system diseases.” Frontiers in cellular and infection microbiology (2024). PMID: 38558851 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  217. [217]

    Alrubaiy L, Mells G, Flack S et al.. “PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis.” Alimentary pharmacology & therapeutics (2019). PMID: 31664722 ↗

    L2OTHERCited in: Special Populations & Prevention
  218. [218]

    de Veer RC, van Hooff MCB, Werner E et al.. “Incidence and prevalence of primary biliary cholangitis in the Netherlands - A nationwide cohort study.” JHEP reports : innovation in hepatology (2024). PMID: 39113899 ↗

    L2COHORTCited in: Special Populations & Prevention
  219. [219]

    Xu C, Li X, Wang H et al.. “Systematic Review and Meta-Analysis of the Effects of Intestinal Microbiota on Liver Disease Using Mendelian Randomization.” JGH open : an open access journal of gastroenterology and hepatology (2025). PMID: 40356607 ↗

    L2SR_OBSCited in: Special Populations & Prevention

Revision History

All updates applied to this page

Loading revisions…